

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Simcere Pharmaceutical Group Limited

先聲藥業集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2096)

APPOINTMENT OF CO-CHIEF EXECUTIVE OFFICER

The board (the “**Board**”) of directors (the “**Directors**”) of Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) hereby announces that, with effect from May 25, 2022, Mr. Tang Renhong (“**Mr. Tang**”), an executive Director of the Company, has been appointed as a Co-chief Executive Officer of the Company. Mr. Tang will assist Mr. Ren Jinsheng, Chairman and the Chief Executive Officer of the Company, in the overall leading of the Group’s research and development affairs and will remain as an executive Director.

The biographical details of Mr. Tang are set out as follows:

Mr. Tang, aged 42, joined the Group in May 2019, and is currently an executive Director and an executive vice president of the Company. Mr. Tang was primarily responsible for the overall management of Shanghai R&D Center and management of the pre-clinical R&D of innovative pharmaceuticals of the Group.

Mr. Tang has nearly 12 years of experience in pharmaceutical research and development and management of pharmaceutical companies. Prior to joining the Group, Mr. Tang served as the vice general manager of Shanghai Shengdi Pharmaceutical Co., Ltd. (上海盛迪醫藥有限公司) from September 2017 to May 2019. From September 2013 to August 2017, Mr. Tang worked as the associate director of China Innovation Center of Astrazeneca Investment (China) Co., Ltd. (阿斯利康投資(中國)有限公司). Before that, he worked at the Novo Nordisk Research Centre China (諾和諾德中國研究發展中心) from June 2009 to September 2013 with the last position there being the head of department. At the beginning of his career, he was a postdoctoral researcher at the University of California, San Francisco from April 2007 to May 2009.

Mr. Tang graduated with a bachelor’s degree in biotechnology from Shanghai Jiao Tong University (上海交通大學) in July 2002. He also obtained a Ph.D. in molecular cell biology from Nanyang Technological University in April 2007.

Mr. Tang has entered into a service contract (“**Service Contract**”) with the Company for his directorship and role as a senior management of the Company. The Service Contract may be renewed in accordance with the articles of association of the Company and the applicable laws, rules and regulations. No separate service contract will be entered into between the Company and Mr. Tang in respect of his appointment as a Co-chief Executive Officer of the Company. The remuneration of Mr. Tang will be determined by the Board with reference to his duties and responsibilities and the prevailing market conditions.

As of the date of this announcement, Mr. Tang was granted 3,000,000 restricted share units (the “**RSUs**”) under the restricted share unit scheme adopted by the Company on May 20, 2021, and is deemed to be interested in 3,000,000 underlying shares of the Company in respect of such RSUs within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed above, as of the date of this announcement, Mr. Tang has confirmed that (i) he does not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, (ii) he does not have any other relationship with any Director, senior management or substantial shareholders or controlling shareholders of the Company, (iii) he is not interested or deemed to be interested in any other shares, underlying shares or debentures of the Company within the meaning of Part XV of the SFO, (iv) there is no other information that is required to be disclosed pursuant to any of the requirements under Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and (v) there is no other matters that need to be brought to the attention of the shareholders of the Company relating to his appointment as a Co-chief Executive Officer of the Company.

The Board would like to express its warmest welcome to Mr. Tang in his new position as a Co-chief Executive Officer of the Company.

By order of the Board of
Sincere Pharmaceutical Group Limited
Mr. Ren Jinsheng
Chairman and Chief Executive Officer

Hong Kong, May 25, 2022

As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.